Literature DB >> 24292388

Species-specific inflammatory responses as a primary component for the development of glomerular lesions in mice and monkeys following chronic administration of a second-generation antisense oligonucleotide.

Kendall S Frazier1, Cécile Sobry2, Victoria Derr3, Mike J Adams4, Cathaline Den Besten5, Sjef De Kimpe5, Ian Francis4, Tracy L Gales6, Richard Haworth4, Shaun R Maguire4, Rosanna C Mirabile6, David Mullins6, Bernard Palate2, Yolanda Ponstein-Simarro Doorten5, James E Ridings4, Marshall S Scicchitano6, Jérémy Silvano2, Jennie Woodfine4.   

Abstract

Chronic administration of drisapersen, a 2'-OMe phosphorothioate antisense oligonucleotide (AON) to mice and monkeys resulted in renal tubular accumulation, with secondary tubular degeneration. Glomerulopathy occurred in both species with species-specific characteristics. Glomerular lesions in mice were characterized by progressive hyaline matrix accumulation, accompanied by the presence of renal amyloid and with subsequent papillary necrosis. Early changes involved glomerular endothelial hypertrophy and degeneration, but the chronic glomerular amyloid and hyaline alterations in mice appeared to be species specific. An immune-mediated mechanism for the glomerular lesions in mice was supported by early inflammatory changes including increased expression of inflammatory cytokines and other immunomodulatory genes within the renal cortex, increased stimulation of CD68 protein, and systemic elevation of monocyte chemotactic protein 1. In contrast, kidneys from monkeys given drisapersen chronically showed less severe glomerular changes characterized by increased mesangial and inflammatory cells, endothelial cell hypertrophy, and subepithelial and membranous electron-dense deposits, with ultrastructural and immunohistochemical characteristics of complement and complement-related fragments. Lesions in monkeys resembled typical features of C3 glomerulopathy, a condition described in man and experimental animals to be linked to dysregulation of the alternative complement pathway. Thus, inflammatory/immune mechanisms appear critical to glomerular injury with species-specific sensitivities for mouse and monkey. The lower observed proinflammatory activity in humans as compared to mice and monkeys may reflect a lower risk of glomerular injury in patients receiving AON therapy.
© 2014 by The Author(s).

Entities:  

Keywords:  amyloid; glomerulonephritis; hyaline glomerulopathy.; monkey pathology; mouse pathology; renal; safety assessment

Mesh:

Substances:

Year:  2013        PMID: 24292388     DOI: 10.1177/0192623313505781

Source DB:  PubMed          Journal:  Toxicol Pathol        ISSN: 0192-6233            Impact factor:   1.902


  10 in total

1.  Preclinical Evaluation of the Renal Toxicity of Oligonucleotide Therapeutics in Mice.

Authors:  Lucía Echevarría; Aurelie Goyenvalle
Journal:  Methods Mol Biol       Date:  2022

2.  Comparison of Renal Amyloid and Hyaline Glomerulopathy in B6C3F1 Mice: An NTP Retrospective Study.

Authors:  Jessica S Hoane; Crystal L Johnson; James P Morrison; Susan A Elmore
Journal:  Toxicol Pathol       Date:  2016-03-21       Impact factor: 1.902

3.  Safety, Tolerability, and Pharmacokinetics of ARC-520 Injection, an RNA Interference-Based Therapeutic for the Treatment of Chronic Hepatitis B Virus Infection, in Healthy Volunteers.

Authors:  Thomas Schluep; Jason Lickliter; James Hamilton; David L Lewis; Ching-Lung Lai; Johnson Yn Lau; Stephen A Locarnini; Robert G Gish; Bruce D Given
Journal:  Clin Pharmacol Drug Dev       Date:  2016-12-12

Review 4.  The Use of Tricyclo-DNA Oligomers for the Treatment of Genetic Disorders.

Authors:  Philippine Aupy; Lucía Echevarría; Karima Relizani; Aurélie Goyenvalle
Journal:  Biomedicines       Date:  2017-12-22

5.  From the Cover: The Minipig is a Suitable Non-Rodent Model in the Safety Assessment of Single Stranded Oligonucleotides.

Authors:  Annamaria Braendli-Baiocco; Matthias Festag; Kamille Dumong Erichsen; Robert Persson; Michael J Mihatsch; Niels Fisker; Juergen Funk; Susanne Mohr; Rainer Constien; Corinne Ploix; Kevin Brady; Marco Berrera; Bernd Altmann; Barbara Lenz; Mudher Albassam; Georg Schmitt; Thomas Weiser; Franz Schuler; Thomas Singer; Yann Tessier
Journal:  Toxicol Sci       Date:  2017-05-01       Impact factor: 4.849

Review 6.  Dystrophic Cardiomyopathy-Potential Role of Calcium in Pathogenesis, Treatment and Novel Therapies.

Authors:  Victoria P A Johnstone; Helena M Viola; Livia C Hool
Journal:  Genes (Basel)       Date:  2017-03-24       Impact factor: 4.096

7.  Efficacy and Safety Profile of Tricyclo-DNA Antisense Oligonucleotides in Duchenne Muscular Dystrophy Mouse Model.

Authors:  Karima Relizani; Graziella Griffith; Lucía Echevarría; Faouzi Zarrouki; Patricia Facchinetti; Cyrille Vaillend; Christian Leumann; Luis Garcia; Aurélie Goyenvalle
Journal:  Mol Ther Nucleic Acids       Date:  2017-06-22       Impact factor: 8.886

Review 8.  The Nonclinical Safety Profile of GalNAc-conjugated RNAi Therapeutics in Subacute Studies.

Authors:  Maja M Janas; Carole E Harbison; Victoria K Perry; Brenda Carito; Jessica E Sutherland; Akshay K Vaishnaw; Natalie D Keirstead; Garvin Warner
Journal:  Toxicol Pathol       Date:  2018-08-23       Impact factor: 1.902

9.  Therapy with 2'-O-Me Phosphorothioate Antisense Oligonucleotides Causes Reversible Proteinuria by Inhibiting Renal Protein Reabsorption.

Authors:  Manoe J Janssen; Tom T G Nieskens; Tessa A M Steevels; Pedro Caetano-Pinto; Dirk den Braanker; Melissa Mulder; Yolanda Ponstein; Shaun Jones; Rosalinde Masereeuw; Cathaline den Besten; Martijn J Wilmer
Journal:  Mol Ther Nucleic Acids       Date:  2019-09-06       Impact factor: 8.886

Review 10.  Development of therapeutic splice-switching oligonucleotides.

Authors:  Petra Disterer; Adrianna Kryczka; Yuqi Liu; Yusef E Badi; Jessie J Wong; James S Owen; Bernard Khoo
Journal:  Hum Gene Ther       Date:  2014-06-19       Impact factor: 5.695

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.